Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to -$12.3 million.

  • Contineum Therapeutics' Free Cash Flow fell 9668.85% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.8 million, marking a year-over-year decrease of 5535.53%. This contributed to the annual value of -$33.4 million for FY2024, which is 27617.64% down from last year.
  • According to the latest figures from Q3 2025, Contineum Therapeutics' Free Cash Flow is -$12.3 million, which was down 9668.85% from -$15.7 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Free Cash Flow high stood at $40.6 million for Q2 2023, and its period low was -$15.7 million during Q2 2025.
  • Over the past 3 years, Contineum Therapeutics' median Free Cash Flow value was -$8.6 million (recorded in 2024), while the average stood at -$5.2 million.
  • Within the past 5 years, the most significant YoY rise in Contineum Therapeutics' Free Cash Flow was 585.67% (2024), while the steepest drop was 12120.41% (2024).
  • Over the past 3 years, Contineum Therapeutics' Free Cash Flow (Quarter) stood at -$11.0 million in 2023, then increased by 5.86% to -$10.4 million in 2024, then fell by 18.59% to -$12.3 million in 2025.
  • Its last three reported values are -$12.3 million in Q3 2025, -$15.7 million for Q2 2025, and -$14.5 million during Q1 2025.